Koos Boeve

31 General introduction and scope of this thesis cell carcinoma. Oral Oncol 2015 May;51(5):464-469. 76. Graveland AP, Braakhuis BJ, Eerenstein SE, de Bree R, Bloemena E, de Maaker M, et al. Molecular diagnosis of minimal residual disease in head and neck cancer patients. Cell Oncol (Dordr) 2012 Oct;35(5):367-375. 77. Tasche KK, Buchakjian MR, Pagedar NA, Sperry SM. Definition of “Close Margin” in Oral Cancer Surgery and Association of Margin Distance With Local Recurrence Rate. JAMA Otolaryngol Head Neck Surg 2017 Dec 1;143(12):1166-1172. 78. Nason RW, Binahmed A, Pathak KA, Abdoh AA, Sandor GK. What is the adequate margin of surgical resection in oral cancer? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009 May;107(5):625- 629. 79. Tan HK, Saulnier P, Auperin A, Lacroix L, Casiraghi O, Janot F, et al. Quantitative methylation analyses of resection margins predict local recurrences and disease- specific deaths in patients with head and neck squamous cell carcinomas. Br J Cancer 2008 Jul 22;99(2):357-363. 80. Braakhuis BJ, Bloemena E, Leemans CR, Brakenhoff RH. Molecular analysis of surgical margins in head and neck cancer: more than a marginal issue. Oral Oncol 2010 Jul;46(7):485-491. 81. Yanamoto S, Yamada S, Takahashi H, Yoshitomi I, Kawasaki G, Ikeda H, et al. Clinicopathological risk factors for local recurrence in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2012 Oct;41(10):1195-1200. 82. van der Hem PS, Nauta JM, van der Wal JE, Roodenburg JL. The results of CO2 laser surgery in patients with oral leukoplakia: a 25 year follow up. Oral Oncol 2005 Jan;41(1):31-37. 83. Mogedas-Vegara A, Hueto-Madrid JA, Chimenos-Kustner E, Bescos-Atin C. Oral leukoplakia treatment with the carbon dioxide laser: A systematic review of the literature. J Craniomaxillofac Surg 2016 Apr;44(4):331-336. 84. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics- driven oncology. Nat Rev Genet 2019 Feb;20(2):71-88. 85. Arantes LMRB, De Carvalho AC, Melendez ME, Lopes Carvalho A. Serum, plasma and saliva biomarkers for head and neck cancer. Expert Rev Mol Diagn 2018 Jan;18(1):85-112. 86. van Ginkel JH, Huibers MMH, van Es RJJ, de Bree R, Willems SM. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients. BMC Cancer 2017 Jun 19;17(1):428-017-3424-0. 87. Ovchinnikov DA, Cooper MA, Pandit P, Coman WB, Cooper-White JJ, Keith P, et al. Tumor-suppressor Gene Promoter Hypermethylation in Saliva of Head and Neck Cancer Patients. Transl Oncol 2012 Oct;5(5):321-326. 88. Aggarwal S, Sharma SC, Das SN. Galectin-1 and galectin-3: plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population. Clin Chim Acta 2015 Mar 10;442:13-21. 89. van der Meulen TA, Harmsen H, Bootsma H, Spijkervet F, Kroese F, Vissink A. The microbiome-systemic diseases connection. Oral Dis 2016 Nov;22(8):719- 734.